Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539

Neuro-Oncology

Volumn 18, Issue 4, 2016, Pages 565-574

  Rogers, C Leland ^a   Perry, Arie ^b   Pugh, Stephanie ^c   Vogelbaum, Michael A ^d   Brachman, David ^e   McMillan, William ^f   Jenrette, Joseph ^g   Barani, Igor ^b   Shrieve, Dennis ^h   Sloan, Andy ⁱ   Bovi, Joseph ^j   Kwok, Young ^k   Burri, Stuart H ^l   Chao, Samuel T ^d   Spalding, Aaron C ^m   Anscher, Mitchell S ^a   Bloom, Beatrice ⁿ   Mehta, Minesh ^k  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Arizona Oncology Services   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^l CAROLINAS MEDICAL CENTER   (United States)

^m Norton Cancer Institute   (United States)

ⁿ NORTH SHORE UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

concordance; cooperative group trial; meningioma; pathology; tumor grade

Indexed keywords

ARTICLE; BRAIN INVASION; CANCER GRADING; CANCER REGISTRY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MENINGIOMA; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; TUMOR INVASION; WORLD HEALTH ORGANIZATION; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; MENINGEAL NEOPLASMS; MULTICENTER STUDY; OBSERVER VARIATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS;

COHORT STUDIES; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM GRADING; OBSERVER VARIATION; PROGNOSIS;

EID: 84966686843     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov247     Document Type: Article

References (32)

1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16: iv1-iv64.
2. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088-1095.
3. Pearson BE, Markert JM, Fisher WS, et al. Hitting a moving target: Evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008;24(5):E3.
4. Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer. 2002;94(5):1538-1547.
5. Korshunov A, Shishkina L, Golanov A. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. Int J Cancer. 2003;104(6):728-734.
6. Combs SE, Schulz-Ertner D, Debus J, von Deimling A, Hartmann C. Improved correlation of the neuropathologic classification according to adapted World Health Organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys. 2011;81(5):1415-1421.
7. Domingues PH, Sousa P, Otero Á, et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol. 2014;16(5):735-747.
8. Olar A, Wani KM, Sulman EP, et al. Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. Brain Pathol. 2015;25(3):266-275.
9. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360-363.
10. Cushing H. The meningiomas (dural endotheliomas). Their source and favoured seats of origin. Brain. 1922;45:282-316.
11. Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol. 2012;5(3):231-242.
12. Scheithauer BW. Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol. 2009;19(4):551-564.
13. Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol. 2010;99:433-443.
14. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. Amer J Surg Pathol. 1997;21:1455-1465.
15. Perry A, Scheithauer BW, Stafford SL, et al. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients. Cancer. 1999;85:2046-2056.
16. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol. 2005;31:141-149.
17. Kondziolka D, Mathieu D, Lunsford LD, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008;62(1):53-60.
18. Kaur G, Sayegh ET, Larson A, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014;16(5):628-636.
19. Perry A. Meningiomas. In:McLendon R, Rosenblum M, Bigner DD, eds.Russell & Rubinstein's Pathology of Tumors of the Nervous System. 7th ed. London, England: Hodder Arnold; 2006:427-474.
20. Lurkin A, Ducimetiére F, Vince DR, et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpres region. BMC Cancer. 2010;10:150.
21. Ray-Coquard I, Montesco MC, Coindre JM, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol. 2012;23(9):2442-2449.
22. Scott CB, Nelson JS, Farnan NC, et al. Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. Cancer. 1995;76:307-313.
23. Perry A, Brat DJ. Meningiomas. In: Perry A, Brat DJ, eds. Practical Surgical Neuropathology: A Diagnostic Approach. Philadelphia, PA: Churchill Livingstone Elsevier; 2010.
24. Lee Y, Liu J, Patel S, et al. Genomic landscape of meningiomas. Brain Pathol. 2010;20(4):751-762.
25. Jensen R, Lee J. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. Neurosurgery. 2012;71(1):146-156.
26. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79:1381-1393.
27. Aldape K, Simmons ML, Davis RL, et al. Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer. 2000;88:2342-2349.
28. Prayson RA, Agamanolis DP, Cohen ML, et al. Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci. 2000;175:33-39.
29. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545-551.
30. Hildebrand J, Gorlia T, Kros JM, et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008;44:1210-1216.
31. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360-369.
32. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-5880.